Asep Inc. Obtains Patent Approval for Its Sepsis Diagnostic Technology in 13 European Countries and Australia


VANCOUVER, BC, November 7, 2022 /CNW/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that the company’s sepsis diagnostic technology, called SepsetER TMhas successfully received patent approval in 13 European countries as well as in Australia. The Company received confirmation of its European patent (EP) 3117030 from its patent attorneys on August 29, 2022and this patent was then validated in Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Swiss and the United Kingdom, representing 400 million people. The Company has also obtained a patent in Australia (Australian Patent No. AU2020201564B2), issued July 16, 2022.

Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)

The patents, licensed exclusively to Asep Inc.’s subsidiary, Sepset Biosciences Inc., validate the company’s unique and clinically feasible AI-based approach to diagnosing sepsis, a disease that causes more than 11 million deaths per year worldwide. The technology, named SepsetEmergency roomis a blood-based gene expression test developed under the leadership of UBC’s Principal Microbiologist and Founding Director and current CEO of Asep Inc., Dr. Robert E. W. Hancock. The test enables early and accurate diagnosis of severe incidences of fatal sepsis, which is also the cause of death in most severe COVID-19 patients.

The patents also provide a solid foundation for the Company’s activities as the test is in advanced development and in preparation for formal 510(k) clinical studies. Since SeptemberEmergency room signature has already been validated and refined in more than 700 patients with sepsis and severe COVID-19 to date, the company is looking to duplicate it in a formal trial. In the area of ​​diagnostics, the 510(k) pathway involves a single clinical study which, if successful, will lead to approval by the United States Food & Drug Administration (FDA). Once approved, the test will be marketed for use in emergency rooms and intensive care units around the world, enabling physicians to quickly make informed patient care decisions that will improve prognosis and survival.

The SepsetEmergency room test detects the dysfunctional immune response underlying sepsis when patients first enter the emergency room. The test is a blood-based gene expression test that is simple to perform using equipment available in most hospital laboratories, and results are obtained in approximately 60 to 90 minutes. Current diagnostic tools provide results after approximately 8 to 36 hours, which often delays the start of treatment. SeptemberEmergency room is designed to allow doctors to quickly predict the severity of the disease and thus trigger urgent treatment of the patient. The patent licensing agreement gives Asep Inc.’s subsidiary, Sepset Biosciences Inc., exclusive worldwide rights to develop the sepsis severity signature into a diagnostic test and bring the test to market.

CEO dr. Robert E. W. Hancock said, “Patents are the cornerstone of biotechnology. This validates the novelty of our technology in the main markets.

Tim MurphyChief Operating Officer, commented, “The expansion of Asep Inc.’s patent coverage in Europe and Australia represents an important step for the company towards the commercialization of the SepsetEmergency room test.


Asep Medical Inc. ( is dedicated to addressing antibiotic failure by developing new solutions for significant unmet medical needs. The company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) which are both in the advanced development of the two proprietary diagnostic tools, enabling the early and rapid identification of severe sepsis as well as broad-spectrum therapies. agents for combating multidrug resistant biofilm infections.

Sepset Biosciences Inc. ( is developing diagnostic technology that involves a patient’s gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetEmergency room is a blood-based gene expression test that is simple to perform and results are obtained in approximately one hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate treatments and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc. ( peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, otolaryngology, sinusitis, orthopedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.


This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. These statements include, but are not limited to, the successful completion of clinical testing of our Sepsis diagnostic test and its anticipated filing for regulatory approval; and conducting preclinical studies on our lead drug, in the hope that this will lead to accelerated clinical trials. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management as of the date they are made and are subject to various risks (including the risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the company profile at and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. applicable expressly so requires.



Show original content to download multimedia: html

SOURCEASEP Medical Holdings Inc.



Show original content to download multimedia:

Source link

Comments are closed.